Does UPMC Health Plan Cover Eliquis (Apixaban)?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) manufactured jointly by Bristol Myers Squibb and Pfizer. The FDA approved it in 2012 for reducing stroke risk in non-valvular atrial fibrillation, and it carries additional approvals for deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and post-orthopedic-surgery thromboprophylaxis. 1

Why Anticoagulant Coverage Is a High-Stakes Question

Atrial fibrillation affects an estimated 2.7 to 6.1 million Americans, according to the CDC. 2 Patients with AFib face a roughly five-fold elevated stroke risk compared with people in normal sinus rhythm. Continuous, uninterrupted anticoagulation is the standard of care for most AFib patients with a CHA2DS2-VASc score of 2 or higher in men or 3 or higher in women, per American Heart Association guidelines. 3

Gaps in coverage can translate directly into lapses in therapy, which increase stroke risk. That is why understanding exactly how your UPMC plan handles Eliquis before you fill the prescription matters.

Clinical Evidence Behind Eliquis

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with AFib and at least one additional risk factor. Apixaban reduced stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; P<0.001), reduced major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001), and reduced all-cause mortality by 11% (3.52% vs. 3.94% per year; P=0.047). 4

These data are why the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation states: "For patients with AF and elevated stroke risk, DOACs are preferred over VKAs for stroke prevention given their superior efficacy, safety, and ease of use." 3

How UPMC Health Plan Formularies Work

UPMC Health Plan is one of the largest integrated health insurers in western Pennsylvania, covering more than 4 million members across commercial, Medicare Advantage, Medicaid (CHIP/Medical Assistance), and Children's Health Insurance Program plans. Each product line maintains its own drug formulary, a tiered list of covered medications.

Formulary Tiers Explained

Most UPMC formularies use a five-tier structure:

• Tier 1: Generic drugs, lowest cost-sharing
• Tier 2: Preferred brand drugs, moderate cost-sharing
• Tier 3: Non-preferred brand drugs, higher cost-sharing
• Tier 4: Specialty drugs, highest cost-sharing (often 25 to 33% coinsurance)
• Tier 5 (some plans): Specialty-plus or excluded drugs

Eliquis lands at Tier 3 on many UPMC commercial plans and at Tier 3 or Tier 4 on Medicare Advantage plans, though the exact tier changes annually with each plan year formulary update. The 2025 UPMC for Life Medicare Advantage formulary, for example, places apixaban at Tier 3 with prior authorization required. 5

Why Tier Placement Changes Year to Year

Drug manufacturers negotiate rebate contracts with Pharmacy Benefit Managers (PBMs) annually. A drug that was Tier 3 in 2024 can shift to Tier 4 in 2025 if a new generic alternative joins the formulary or if rebate negotiations change. Generic apixaban (manufactured by multiple companies following the 2019 patent dispute ruling) became widely available in the United States in late 2023, which has already influenced how some plans position branded Eliquis relative to generic apixaban. 6

Prior Authorization Requirements for Eliquis Under UPMC

Prior authorization (PA) is a requirement that your prescribing clinician obtain formal insurer approval before a prescription will be covered. UPMC Health Plan requires PA for Eliquis on most plan types.

What Triggers a PA Request

UPMC's PA criteria for apixaban typically include documentation of:

1. A covered FDA-approved indication (AFib, DVT, PE, or post-surgical prophylaxis)
2. A confirmed diagnosis with supporting clinical notes or diagnostic codes
3. In some commercial plans, evidence that a preferred Tier 1 or Tier 2 anticoagulant (such as generic warfarin) was considered or tried

The prescribing physician submits the PA request through UPMC's provider portal or via fax. UPMC Health Plan is required under Pennsylvania Insurance Department rules to respond to standard PA requests within 14 calendar days and urgent requests within 72 hours.

Step Therapy and Its Implications

Some UPMC commercial plans impose step therapy for Eliquis, meaning the plan requires a trial of a lower-tier anticoagulant first. Warfarin remains the most common step-therapy requirement. Clinicians can submit a step-therapy exception request if:

• The patient has a documented hypersensitivity or contraindication to warfarin
• The patient previously failed warfarin (subtherapeutic INR control, major bleeding, or intolerance)
• The patient's condition makes frequent INR monitoring clinically impractical

The ACC's 2023 guidelines note that DOACs have "a more predictable pharmacokinetic and pharmacodynamic profile than warfarin, eliminating the need for routine coagulation monitoring." 3 That clinical argument can be used directly in a step-therapy exception letter.

UPMC Medicare Advantage and Eliquis Coverage

UPMC for Life is UPMC Health Plan's Medicare Advantage product line. Coverage rules for Eliquis under Part D (the prescription drug benefit component of Medicare Advantage) follow both CMS regulations and UPMC's plan-specific formulary decisions.

The Part D Coverage Gap and Eliquis Cost

Under standard 2025 Medicare Part D benefit design, out-of-pocket drug costs are capped at $2,000 per year, a change introduced by the Inflation Reduction Act of 2022. 7 Before hitting the out-of-pocket cap, patients in the coverage gap pay 25% of drug costs for brand-name medications. At a retail price of roughly $600 per month for branded Eliquis, that means $150 per month during the gap phase.

Medicare Extra Help (Low-Income Subsidy)

Medicare beneficiaries with limited income and resources may qualify for Extra Help (also called the Low-Income Subsidy or LIS), which dramatically reduces Part D cost-sharing. In 2025, full Extra Help recipients pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs per fill. 8 Patients should contact the Social Security Administration or UPMC Health Plan's member services directly to apply.

Manufacturer Copay Cards Do Not Apply to Medicare

Bristol Myers Squibb and Pfizer offer a commercial copay assistance card that reduces branded Eliquis cost to as low as $10 per month for commercially insured patients. Federal anti-kickback statutes prohibit using manufacturer copay cards for federally funded insurance programs including Medicare and Medicaid. Medicare patients who cannot afford Eliquis under UPMC for Life should pursue Extra Help, a Part D exception request, or ask their cardiologist about switching to generic apixaban, which carries the same active compound at a fraction of the branded price.

UPMC Medicaid (Medical Assistance) and Eliquis

Pennsylvania's Medicaid program, called Medical Assistance (MA), covers apixaban through managed care organizations (MCOs) that contract with the Pennsylvania Department of Human Services. UPMC Health Plan participates as an MCO.

Formulary Position on UPMC Community Care

On UPMC Community Care (the Medicaid MCO product), apixaban is generally covered with PA. The Pennsylvania Department of Human Services publishes a preferred drug list (PDL) for Medical Assistance, and apixaban appears as a covered non-preferred DOAC with PA required. 9 Copays for Medicaid beneficiaries are very low or zero depending on eligibility category.

How to Check Your Specific UPMC Plan's Eliquis Coverage

Coverage details vary by individual plan year and member ID. The most reliable approach is a multi-step verification process.

Step 1: Use the UPMC Formulary Search Tool

Go to the UPMC Health Plan website, manage to "Pharmacy," and use the formulary drug search to look up apixaban or Eliquis. Enter your plan name and plan year. The search returns the tier, any quantity limits, and whether PA is required.

Step 2: Call the Member Services Number on Your Insurance Card

The member services team can confirm real-time formulary status, quote your specific tier cost-sharing based on your deductible status, and tell you whether a PA has already been initiated by your prescriber.

Step 3: Ask Your Prescribing Clinician to Submit a PA

If PA is required, your cardiologist or primary care physician should submit the PA request with diagnosis codes, clinical notes supporting the AFib or VTE diagnosis, and any prior anticoagulant history. The clinician's office typically handles this; patients should follow up if they have not heard back within five business days.

Step 4: Request a Formulary Exception if PA Is Denied

If the PA is denied, UPMC Health Plan offers a formal formulary exception and appeals process. For Medicare Advantage members, CMS mandates a specific appeals timeline: plans must respond to standard exception requests within 72 hours and expedited requests within 24 hours. 10

Eliquis Cost Without Insurance or With High Cost-Sharing

If coverage is denied or cost-sharing is prohibitive, several options exist.

Generic Apixaban

Generic apixaban entered the U.S. Market in late 2023 following a court settlement between Bristol Myers Squibb/Pfizer and generic manufacturers. It carries the same 2.5 mg and 5 mg tablet strengths, the same twice-daily dosing, and identical bioequivalence standards. A 60-tablet supply (one month at 5 mg twice daily) has been available at major pharmacy chains and discount programs for $40 to $80 per month, compared with roughly $600 per month for branded Eliquis. 6 UPMC formularies may place generic apixaban at a lower tier than the brand, making it the cost-preferred option for most insured patients.

Bristol Myers Squibb / Pfizer Eliquis Copay Card

Commercially insured patients (not Medicare or Medicaid) who meet eligibility criteria can enroll in the manufacturer copay assistance program. As of 2025, eligible patients pay as little as $10 for a 30-day supply, with a maximum annual benefit of $6,400. Enrollment is available at the official Eliquis patient support website or by calling 1-855-ELIQUIS.

GoodRx and Pharmacy Discount Programs

GoodRx, Mark Cuban's Cost Plus Drugs, and Amazon Pharmacy all list generic apixaban pricing. As of early 2025, Cost Plus Drugs lists generic apixaban 5 mg (60 tablets) at under $50 with a transparent markup. These discount programs are used outside of insurance and cannot be combined with insurance benefits in the same transaction.

HealthRX Eliquis Coverage Decision Framework

When a patient asks whether UPMC will cover Eliquis, the clinical-administrative path follows five distinct checkpoints:

1. Confirm indication. Is the diagnosis AFib, DVT, PE, or post-surgical VTE prophylaxis? Off-label use (e.g., antiphospholipid syndrome) faces higher PA denial rates.
2. Check current formulary tier. Pull the plan-year-specific formulary. Generic apixaban tier matters as much as branded Eliquis tier.
3. Assess PA and step-therapy requirements. If step therapy applies, document prior anticoagulant history or contraindications before submitting.
4. Evaluate cost-sharing under current deductible status. A patient who has met their annual deductible pays only the coinsurance percentage, not the full tier cost.
5. Identify assistance programs. Commercial patients: manufacturer card. Medicare patients: Extra Help or Part D exceptions. Medicaid patients: confirm MCO formulary coverage and apply for Medicaid if not yet enrolled.

What Happens if UPMC Denies Eliquis Coverage?

Denial is not the end of the road. UPMC Health Plan, like all insurers regulated under the Affordable Care Act and CMS Medicare rules, must provide a clear reason for denial and a path to appeal.

Internal Appeal

File a first-level internal appeal with UPMC Health Plan within the plan's stated timeframe (typically 60 days from the denial notice for commercial plans, 60 days for Medicare Advantage). Submit a letter from the prescribing clinician explaining the medical necessity, citing ARISTOTLE trial data and guideline recommendations if appropriate.

External Review

If the internal appeal is denied, Pennsylvania law allows members to request an independent external review through the Pennsylvania Insurance Department. 11 External reviewers are independent of UPMC and issue binding decisions.

Expedited Appeals for Urgent Medical Need

A patient currently hospitalized for a thromboembolic event or with active AFib and high CHA2DS2-VASc score qualifies for an expedited appeal. UPMC must respond within 72 hours for standard expedited commercial appeals and within 24 hours for Medicare Advantage expedited appeals. 10

Clinical Considerations: When to Use Eliquis vs. Other DOACs

Formulary coverage sometimes pushes patients toward a different anticoagulant. Whether that substitution is appropriate depends on the clinical scenario.

Apixaban vs. Rivaroxaban

Rivaroxaban (Xarelto) is often placed at a lower formulary tier than Eliquis on some UPMC plans. Both are factor Xa inhibitors. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AFib (1.7% vs. 2.2% per year; P<0.001 for non-inferiority). 12 However, the twice-daily dosing of apixaban may provide more consistent factor Xa inhibition over 24 hours compared with once-daily rivaroxaban, a consideration some cardiologists weigh when recommending against substitution.

Apixaban vs. Dabigatran

Dabigatran (Pradaxa) is a direct thrombin inhibitor rather than a factor Xa inhibitor. RE-LY (N=18,113) showed dabigatran 150 mg twice daily reduced stroke by 34% vs. Warfarin but carried higher rates of gastrointestinal bleeding. 13 Patients with significant gastrointestinal disease may tolerate apixaban better, which supports a PA exception based on tolerability.

Reduced-Dose Apixaban (2.5 mg Twice Daily)

Patients meeting two or more of three criteria (age 80 or older, weight 60 kg or under, or serum creatinine 1.5 mg/dL or above) are dosed at 2.5 mg twice daily per the FDA-approved labeling. 1 This dose reduction was validated in ARISTOTLE's pre-specified subgroup analysis; prescribers should document which criteria the patient meets in the PA submission.

Talking to Your Cardiologist About Coverage and Switching

Insurance coverage should inform but not override clinical decision-making. The 2023 ACC/AHA AFib guidelines state that "the choice of anticoagulant should be individualized based on patient-specific factors including renal function, adherence, cost, and patient preference." 3

If UPMC's formulary makes branded Eliquis unaffordable, discuss these options with your cardiologist:

• Switching to generic apixaban (same molecule, significantly lower cost)
• Switching to a preferred-tier DOAC (rivaroxaban or dabigatran) if clinically appropriate
• Pursuing the PA and appeals process before switching
• Enrolling in the manufacturer assistance program if commercially insured

A 2021 analysis in JAMA Internal Medicine found that out-of-pocket costs exceeding $50 per month are independently associated with medication non-adherence in anticoagulated AFib patients, with adherence rates dropping by approximately 14 percentage points in cost-sensitive populations. 14 Non-adherence in this population carries direct stroke risk, making cost resolution a medical priority, not merely an administrative one.